tbuckley/cabot-search huggingface dataset:
An Audit of ERCPS Performed in a Single Regional Referral Centre
Authors: AR Aftab, A Coss, SA Zulquernain, G Courtney
Journal: Endoscopy (2004)

Endoscopic retrograde cholangiopancreatography (ERCP) is a highly specialised procedure used in the diagnosis and treatment of a range of biliary and pancreatic diseases which might otherwise require surgical intervention. However, relatively high rates of complications (4–10%) including death (0.2–0.4%) have been reported.
THE IMPACT OF RUNNING LEVEL ON THE ASSOCIATION BETWEEN RUNNING DISTANCE AND INJURY RISK
Authors: Camma Damsted, Rasmus Oestergaard Nielsen, Laurent Malisoux
Journal: British Journal of Sports Medicine (2017)

Background Running distance has previously been identified as a risk factor for running-related injury. It is likely that the runner's fitness level may also influence injury risk. Objective To investigate if running level modifies the association between cumulated running distance over the previous week and injury risk. Design Prospective cohort study with a 6-month follow-up. Setting Recreational runners. Participants Injury free recreational runners (n=372) were required to report all running activity as well as any injury using a dedicated Internet platform. Assessment of Risk Factors The main exposure was cumulated running distance over the week prior to a given session (time-dependent exposure) and was dichotomized into low&lt;20 km (reference group), and high≥20 km . Running level was defined as the average running speed during follow-up and was dichotomized into fast runners≥10 km/h and slow runners&lt;10 km/h. Main Outcome Measurements First running-related injury based on a 1-day time loss definition. Results In the crude analysis, a lower injury rate was observed when the runners cumulated a high running distance prior to a given session (hazard ratio (HR)=0.43; 95% confidence interval (95% CI)=0.28–0.66). After stratification according to running level, a significant lower injury rate was found for slow runners (HR=0.32; 95% CI=0.18–0.60) when they cumulated a high running distance prior to a given session, while the injury rate did not differ between exposure states for fast runners (HR=0.78; 95% CI=0.37–1.64). Based on the hazard ratios from the stratified analysis, it appears that low running level modifies the association between cumulated running distance over the previous week and injury risk with a factor of 2.43. Conclusions Running level should be taken into account when analysing the association between training-related risk factor and injury risk.
Effect of concussion history on sway velocity and bess scores in division i football players
Authors: Theresa Miyashita, Benson Batchelder
Journal: British Journal of Sports Medicine (2017)

Objective The purpose of our study was to investigate if concussion history has an effect on sway velocity and BESS scores in Division I football players. Design Cohort Study Setting Division I University Participants 75 Division I football players (age=19.76 ± 1.1, height=72.41” ± 2.19”, weight=222.55 lbs ± 38.17 lbs) Outcome measures Correlation statistics determined the association between concussion history, sway velocity, and BESS errors. Sway velocity was determined by performing the BESS test on a force plate, and BESS errors were determined by one experienced evaluator. Players performed the six trials of the BESS test: three stances on two surfaces. Main results There were no statistical associations between concussion history and sway velocity or BESS errors. There were significant and positive correlations between sway velocity and BESS errors, indicating as sway velocity increased so did the number of errors, on the following trials: single leg firm surface ( r s =0.62, p &lt;0.001), tandem stance firm surface ( r s =0.72, p ?&lt; 0.001), single leg foam surface ( r s =0.25, p =0.029), tandem stance foam surface ( r s =0.70, p &lt;0.001), and composite scores ( r s =0.68, p &lt;0.001). Conclusions Concussion history does not appear to have an impact on sway velocity measures or BESS scores. However, there was a significant and positive correlation between sway velocity and BESS errors during four of the trials and the composite scores, supporting the validity of the BESS test. Competing interests None.
Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens
Authors: Maciej Lech, Onkar P. Kulkarni, Stephanie Pfeiffer, Emina Savarese, Anne Krug, Cecilia Garlanda, Alberto Mantovani, Hans-Joachim Anders
Journal: The Journal of Experimental Medicine (2008)
Abstract 17: MicroRNA-30c Modulates Diabetes-Induced Cardiac Hypertrophy via PI3K/Akt Signaling Pathway
Authors: Satish K Raut, Akhilesh Kumar, Gurinder B Singh, Rajni Sharma, Uma Saikia, Madhu Khullar
Journal: Circulation Research (2012)

Cardiomyocyte hypertrophy leading to cardiac failure is one of the characteristic alterations in Diabetic Cardiomyopathy. Several regulatory mechanisms mediate altered gene expression in DCM. Alterations in several myocardial miRs have been demonstrated in cardiac hypertrophy but the role of miR-30c in the pathophysiology of diabetes induced cardiac hypertrophy is not known. Objective: miR-30c may be involved in modulating expression of key genes (Rac1, Cdc42 and Pak1) of PI3K/Akt signalling pathway involved in cardiac hypertrophy in DCM. Method: DCM was induced in Wistar rats by STZ-high fat diet combination and animals were sacrificed after 12 weeks of diabetes. The expression of miR-30c, Rac1, Cdc42 and Pak1 genes and markers of hypertrophy (ANP and β-MHC) was studied in cardiac tissues (n=6) and control rats (n=6) by qRT-PCR. Result: We observed 4 fold increased expression of ANP and 2.2 fold of β-MHC genes in DCM group as compared to control group (n=6) (p&lt;0.05). Decreased expression of miR-30c (3.3 fold) was seen in DCM model at 12 weeks compared to control group (n=6) (p&lt;0.05). Expression of three specific targets of miR-30c i.e. Cdc42, Pak1, and Rac1, regulating cardiac hypertrophy, was found to be significantly increased by 1.94 fold, 1.8 fold, and 1.2 fold in cardiac tissues of DCM model respectively and was inversely related to miR-30c expression. Conclusion: Our results suggest that down regulation of miR-30c in cardiac tissue may play a key role in regulation of diabetes associated cardiac hypertrophy by modulating PI3K/Akt signalling pathway.
Objective Quantification of Anterior Chamber Inflammation
Authors: Alessandro Invernizzi, Sylvia Marchi, Raffaella Aldigeri, Valentina Mastrofilippo, Fabiana Viscogliosi, Annamaria Soldani, Chantal Adani, Elena Garoli, Francesco Viola, Luigi Fontana, Peter McCluskey, Luca Cimino
Journal: Ophthalmology (2017)
Evidence for altered levels of IgD in the nasal airway mucosa of patients with chronic rhinosinusitis
Authors: Jin-Young Min, Jayakar V. Nayak, Kathryn E. Hulse, Whitney W. Stevens, Paul A. Raju, Julia H. Huang, Lydia A. Suh, Griet A. Van Roey, James E. Norton, Roderick G. Carter, Caroline P.E. Price, Ava R. Weibman, Ali R. Rashan, Eliver E. Ghosn, Zara M. Patel, Tetsuya Homma, David B. Conley, Kevin C. Welch, Stephanie Shintani-Smith, Anju T. Peters, Leslie C. Grammer, Kathleen E. Harris, Atsushi Kato, Peter H. Hwang, Robert C. Kern, Leonore A. Herzenberg, Robert P. Schleimer, Bruce K. Tan
Journal: Journal of Allergy and Clinical Immunology (2017)
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
Authors: Hiroshi Kitamura, Taiji Tsukamoto, Naoya Masumori, Taro Shibata, Futoshi Kunieda, Hiroyuki Fujimoto, Yoshihiko Hirao, Yasuo Kitamura, Yoshihiko Tomita, Kenichi Tobisu, Masashi Niwakawa, Seiji Naito, Masatoshi Eto, Yoshiyuki Kakehi
Journal: Journal of Clinical Oncology (2013)

4526 Background: Cisplatin-based NAC for patients (pts) with MIBC is considered to provide a 5–8% overall survival (OS) advantage, although several studies failed to prove the survival benefit of NAC. Methods: Eligibility criteria included histologically proven urothelial carcinoma, MIBC (T2-4aN0M0) within 8 weeks from TURBT, PS 0-1, and age 20-75 years old. Patients were randomized to receive 2 cycles of neoadjuvant MVAC followed by RC (NAC arm) or RC alone (RC arm). The primary endpoint was OS. Secondary endpoints were progression-free survival (PFS), surgery-related complications, adverse events during NAC, the percent with no residual tumor in the RC specimens (pT0), and QOL. The sample size was 180 pts in each arm with a one-sided alpha of 5% and a power of 80% to detect a 7% difference in 5-year OS, 45% in the RC arm, and 57% in the NAC arm. Results: From March 2003 to March 2009, 130 pts were randomized to the NAC arm (n=64) and RC arm (n=66). Fifty-nine patients in the NAC arm and 65 in the RC arm underwent cystectomy. The patient registration was terminated early because of slow accrual. At the 2nd interim analysis conducted after the completion of patient accrual, OS of the NAC arm was better than that of the RC arm, although the difference was not statistically significant (HR, 0.65; multiplicity adjusted 99.99%CI, 0.19-2.18; one-sided log-rank p = 0.07). Considering the current situation in which NAC with gemcitabine and cisplatin (GC) is widely used in clinical practice, the Data and Safety Monitoring Committee recommended early publication of the results. PFS of the NAC arm was better than that of the RC arm (HR, 0.61; 95% CI, 0.35-1.06, one-sided log-rank p=0.04). No differences in perioperative complications, other than lymph leakage, were observed between the arms. In the NAC arm and the RC arm, 34% and 9% of the patients had pT0, respectively (p&lt;0.01). In subgroup analyses, OS in almost all subgroups was in favor of NAC. Conclusions: Although NAC with GC is widely used for MIBC, NAC with MVAC can still be considered promising. Clinical trial information: C000000093.
Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy
Authors: Elizabeth A. Sugar, Vidya Venugopal, Jennifer E. Thorne, Kevin D. Frick, Gary N. Holland, Robert C. Wang, Robert Almanzor, Douglas A. Jabs, Janet T. Holbrook
Journal: Ophthalmology (2017)
Irish Higher Medical Training in Gastroenterology; Where are we Now?
Authors: G Doherty, S Byrne, A Coss, D Sadlier, A Moss
Journal: Endoscopy (2004)

Aims: A formal higher medical training scheme in gastroenterology has been in existence for several years but progress in the provision of structured training has not been assessed. We aimed to assess trainee satisfaction and identify problem areas for current SpRs in gastroenterology.
ECG OF INDIAN ATHLETES–ESC VS SEATTLE CRITERIA
Authors: Jahnavi Dande, Anirban Mallick
Journal: British Journal of Sports Medicine (2017)

Background The European Society of Cardiology (ESC) released recommendations in 2010 for the interpretation of 12 lead electrocardiogram (ECG) in athletes. In 2013, the ‘Seattle Criteria’ was published with the aim to improve sensitivity of ECG screening. Objective To compare the sensitivity of these two criteria for Indian athletes. Design Cross sectional ECG data of the female athletes was collected during preparticipation screening. Any athletes with known cardiovascular disease was excluded from the study. Setting ECG was recorded during their entry in the national camp in 2014–15 at the National Institute of Sports. Written informed consent was obtained before the study. Patients (or Participants) The study population consisted of 63 elite female athletes (30 footballers and 33 from athletics) with mean age, height, weight, BMI of 22.71 (SD- 3.30) years, 157.38 (SD- 4.20) cm, 52.29 (SD- 3.87) kg, 21.77 (SD- 1.67) kg/m 2 respectively along with mean training age of 9.79 (SD- 3.08) years. None of them was having any known cardiovascular disorder. Interventions (or Assessment of Risk Factors) The standard 12 lead ECG (RMS vesta 302i) was collected by a physician. Main Outcome Measurements All ECGs had been evaluated and compared as per ESC and Seattle criteria by single investigator. Results 12 (19%) [7(11.1%) with long QT syndrome and 5 (7.9%) with T wave inversion] and 3 (4.8%) [T wave inversion] athletes had abnormal ECG according to ESC and Seattle criteria respectively. Only one (1.5%) among them was detected cardiomyopathy by further investigations. The reduction was due to reclassification of 7 (11.1%) athletes with a redefined QTc interval, 2 (3.1%) with T wave inversion isolated to V 1–2 . Conclusions Using Seattle criteria for the athletes of Indian origin, the false positive ECG has been reduced from 17.5% to 3.3% but still the same athlete with cardiac abnormality can be identified.
Defining asthma and assessing asthma outcomes using electronic health record data: a systematic scoping review
Authors: Mohammad A. Al Sallakh, Eleftheria Vasileiou, Sarah E. Rodgers, Ronan A. Lyons, Aziz Sheikh, Gwyneth A. Davies
Journal: European Respiratory Journal (2017)

There is currently no consensus on approaches to defining asthma or assessing asthma outcomes using electronic health record-derived data. We explored these approaches in the recent literature and examined the clarity of reporting. We systematically searched for asthma-related articles published between January 1, 2014 and December 31, 2015, extracted the algorithms used to identify asthma patients and assess severity, control and exacerbations, and examined how the validity of these outcomes was justified. From 113 eligible articles, we found significant heterogeneity in the algorithms used to define asthma (n=66 different algorithms), severity (n=18), control (n=9) and exacerbations (n=24). For the majority of algorithms (n=106), validity was not justified. In the remaining cases, approaches ranged from using algorithms validated in the same databases to using nonvalidated algorithms that were based on clinical judgement or clinical guidelines. The implementation of these algorithms was suboptimally described overall. Although electronic health record-derived data are now widely used to study asthma, the approaches being used are significantly varied and are often underdescribed, rendering it difficult to assess the validity of studies and compare their findings. Given the substantial growth in this body of literature, it is crucial that scientific consensus is reached on the underlying definitions and algorithms.
Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma.
Authors: Ozturk Ates, Sercan Aksoy, Hasan Yeter, Serkan Akin, Neyran Kertmen, Omer Dizdar, Alev Turker, Ayse Kars
Journal: Journal of Clinical Oncology (2016)

e22524 Background: Synovial sarcoma (SS) is a malignant mesenchymal tumor which comprises 5-10% of all the sarcomas. The risk of local recurrence and metastasis is higher. In this study we aimed to investigate clinicopathologic characteristics of patients with recurrent or metastatic SS. Methods: Total of 44 SS patients followed-up between 2001-2015 years at Hacettepe University Cancer Institute Department of Medical Oncology was evaluated retrospectively. Eleven of them were initially metastatic and 33 of them were recurrent or metastatic during follow-up. Patients were evaluated clinicopathological features, prognostic factors and treatment modalities. Overall survival (OS) and event-free survival (EFS) were evaluated by Kaplan-Meier analysis. Results: The median age at diagnosis of 44 patients was 30 (17-70) years, and 59% (n = 26) of them were female. SS localized 59% (n = 26) of patients in the body and 39% (n = 17) of the patients limbs. Total of 82% of patients was operated. Adjuvant chemotherapy and adjuvant radiotherapy were administered 41% and 36% of patients respectively. Median follow-up time of was 33 (6-175) months. Median OS was 21(14-27) month all groups. Also median OS was 15 (8-21) and 31 (18-43) months in patients metastatic disease at the time of diagnosis and recurrent or metastatic disease during to follow up respectively. This difference was statistically significance (p = 0.034). Most metastatic locations were lung, bone, brain and liver. Chemotherapy as first-line, most of metastatic patients were treated with ifosfamide, mesna, adriamycin (IMA) (34%, n = 15) and cisplatin-etoposide (14%, n = 6). Partial disease was obtained in 18% of the patients, progressive disease in 50% and stable disease in 5% of the patients. Conclusions: Overall survival after metastasis was longer in patient who develops recurrence or metastatic disease than metastatic disease at time of diagnosis.
Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas
Authors: J. J. Vredenburgh, A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, A. Friedman
Journal: Journal of Clinical Oncology (2006)

1506 Background: The prognosis for recurrent malignant gliomas is poor, with a median survival &lt;12 months, median progression-free survival &lt;12 weeks and response rates &lt;20%. Malignant gliomas have high concentrations of VEGF receptors, and the higher the VEGF receptor concentration, the worse the prognosis. Bevacizumab is a humanized IgG1 monoclonal antiblody to VEGF, which is synergistic with chemotherapy for most malignancies. Irinotecan is a topoisomerase 1 inhibitor, and has modest activity against recurrent malignant gliomas. Methods: We report a FDA approved phase II trial of bevacizumab and irinotecan for the treatment of recurrent malignant gliomas. 32 patients were enrolled, 23 with grade IV tumors (glioblastoma multiforme) and 9 with grade III tumors (anaplastic astrocytomas or oligodendrogliomas). All the patients had progressive disease and every patient had received prior radiation therapy and chemotherapy. Patients were treated every other week with bevacizumab 10 mg/kg and irinotecan 125 mg/m 2 for patients not taking enzyme inducing anti-epileptic drugs or 340 mg/m 2 for patients taking enzyme inducing anti-epileptic drugs. Results: The regimen was well tolerated with no CNS hemorrhages or &gt;grade 1 systemic hemorrhages. Four patients were taken off study for thrombotic complications, 2 pulmonary emboli, 1 deep venous thrombus, and one thrombotic stroke. Two patients were discontinued secondary to grade 2 proteinuria and three were discontinued because they required non-neurosurgical surgery, appendectomy, repair of anal fissures and hip stabilization. The response rate was 63% (19 PRs and 1 CR). The median progression-free survival is 24 weeks. The median overall survival has not been reached, and exceeds 6 months. There have been ten deaths due to disease progression. Conclusions: The combination of bevacizumab and irinotecan is safe and one of the most active regimens against malignant gliomas. [Table: see text]
Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis
Authors: Remo Frei, Ruth Ferstl, Caroline Roduit, Mario Ziegler, Elisa Schiavi, Weronika Barcik, Noelia Rodriguez-Perez, Oliver F. Wirz, Marcin Wawrzyniak, Benoit Pugin, Dirk Nehrbass, Marek Jutel, Sylwia Smolinska, Patrycja Konieczna, Christian Bieli, Susanne Loeliger, Marco Waser, Göran Pershagen, Josef Riedler, Martin Depner, Bianca Schaub, Jon Genuneit, Harald Renz, Juha Pekkanen, Anne M. Karvonen, Jean-Charles Dalphin, Marianne van Hage, Gert Doekes, Mübeccel Akdis, Charlotte Braun-Fahrländer, Cezmi A. Akdis, Erika von Mutius, Liam O’Mahony, Roger P. Lauener, Tobias Alfvén, Johan Alm, Anna Bergström, Lars Engstrand, Helen Rosenlund, Niclas Hakansson, Gunnar Lilja, Frederik Nyberg, Jackie Swartz, Magnus Wickman, Johannes Wildhaber, Alex Möller, Bert Brunekreef, Mirian Boeve, Jeroen Douwes, Machteld Huber, Mirjam Matze Gertraud Weiss, Mynda Schreue, Karin B. Michles, Felix Sennhauser, Annika Scheynius, Maija-Riitta Hirvonen, Sami Remes, Marjut Roponen, Pekka Tiittanen, Marie-Laure Dalphin, Vincent Kaulek Gisela Buchele, Markus Ege, Michael Kabesch, Petra Pfefferle, Georg Loss, Anne Hyvärinen
Journal: Journal of Allergy and Clinical Immunology (2017)

Graphical abstractAbstractBackgroundChildhood exposure to a farm environment has been shown to protect against the development of inflammatory diseases, such as allergy, asthma, and inflammatory bowel disease.ObjectiveWe sought to investigate whether both exposure to microbes and exposure to structures of nonmicrobial origin, such as the sialic acid N-glycolylneuraminic acid (Neu5Gc), might play a significant role.MethodsExposure to Neu5Gc was evaluated by quantifying anti-Neu5Gc antibody levels in sera of children enrolled in 2 farm studies: the Prevention of Allergy Risk factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) study (n = 299) and the Protection Against Allergy Study in Rural Environments (PASTURE) birth cohort (cord blood [n = 836], 1 year [n = 734], 4.5 years [n = 700], and 6 years [n = 728]), and we associated them with asthma and wheeze. The effect of Neu5Gc was examined in murine airway inflammation and colitis models, and the role of Neu5Gc in regulating immune activation was assessed based on helper T-cell and regulatory T-cell activation in mice.ResultsIn children anti-Neu5Gc IgG levels correlated positively with living on a farm and increased peripheral blood forkhead box protein 3 expression and correlated inversely with wheezing and asthma in nonatopic subjects. Exposure to Neu5Gc in mice resulted in reduced airway hyperresponsiveness and inflammatory cell recruitment to the lung. Furthermore, Neu5Gc administration to mice reduced the severity of a colitis model. Mechanistically, we found that Neu5Gc exposure reduced IL-17+ T-cell numbers and supported differentiation of regulatory T cells.ConclusionsIn addition to microbial exposure, increased exposure to non–microbial-derived Neu5Gc might contribute to the protective effects associated with the farm environment.